Company Legal Name
Latest Valuation
Founded Year
Headquarter
insitro, Inc. develops advanced drug discovery platforms that leverage machine learning and artificial intelligence to analyze large-scale biological and clinical datasets. Founded in 2018 and headquartered in South San Francisco, the company combines computational biology with experimental validation to identify novel therapeutic targets and optimize drug development processes. By integrating multi-omics data with predictive modeling, insitro aims to reduce the time and cost traditionally associated with pharmaceutical research and development. The company focuses on transforming how drugs are discovered and developed, positioning itself at the intersection of biotechnology and artificial intelligence to accelerate the delivery of life-changing medicines to patients.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.
